From Inflammation to Fibrosis: Novel Insights into the Roles of High Mobility Group Protein Box 1 in Schistosome-Induced Liver Damage

文献类型： 外文期刊

第一作者： Zhong, Haoran

作者： Zhong, Haoran;Gui, Xiang;Hou, Ling;Lv, Rongxue;Jin, Yamei;Zhong, Haoran;Gui, Xiang;Hou, Ling;Lv, Rongxue;Jin, Yamei;Hou, Ling

作者机构：

关键词： schistosomiasis; granulomas; high mobility group protein box 1; hepatic fibrosis; inflammation

期刊名称：PATHOGENS （ 影响因子：4.531； 五年影响因子：4.58 ）

ISSN：

年卷期： 2022 年 11 卷 3 期

页码：

收录情况： SCI

摘要： Schistosomiasis is a chronic helminthic disease of both humans and animals and the second most prevalent parasitic disease after malaria. Through a complex migration process, schistosome eggs trapped in the liver can lead to the formation of granulomas and subsequent schistosome-induced liver damage, which results in high mortality and morbidity. Although praziquantel can eliminate mature worms and prevent egg deposition, effective drugs to reverse schistosome-induced liver damage are scarce. High mobility group box 1 (HMGB1) is a multifunctional cytokine contributing to liver injury, inflammation, and immune responses in schistosomiasis by binding to cell-surface Toll-like receptors and receptors for advanced glycation end products. HMGB1 is increased in the serum of patients with schistosomiasis and enables hepatic stellate cells to adopt a proliferative myofibroblast-like phenotype, which is crucial to schistosome-induced granuloma formation. Inhibition of HMGB1 was found to generate protective responses against fibrotic diseases in animal models. Clinically, HMGB1 presents a potential target for treatment of the chronic sequelae of schistosomiasis. Here, the pivotal role of HMGB1 in granuloma formation and schistosome-induced liver damage, as well the potential of HMGB1 as a therapeutic target, are discussed.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序